Search

Your search keyword '"Tiemann, Katharina"' showing total 152 results

Search Constraints

Start Over You searched for: Author "Tiemann, Katharina" Remove constraint Author: "Tiemann, Katharina"
152 results on '"Tiemann, Katharina"'

Search Results

2. Noninferiority of Artificial Intelligence–Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics

5. MSI testing: What’s new? What should be considered?

6. MSI-Testung: Was ist neu? Was ist zu beachten?

11. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

12. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

13. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

14. supplemental figure legend from Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

15. Supp Figure 1: Cutoff Finder analysis. from Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

16. Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab

17. Atrial Giant Cell Myocarditis as a Cause of Heart Failure

18. 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

22. Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes

23. MSI testing

24. MSI testing : What should be considered?

25. MSI testing What is new? What should be considered? German version

26. MSI testing What's new? What should be considered?

27. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

32. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus

35. BIELEFELDER PERSPEKTIVEN ZUR ÜBERLIEFERUNG IM VERBUND.

37. BERICHTE DER ARBEITSKREISE IN DER MITGLIEDERVERSAMMLUNG.

39. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

40. BERICHTE DER ARBEITSKREISE IN DER MITGLEDERVERSAMMLUNG.

41. Abstract PD5-7: PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer

42. Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells

43. Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer

44. L-arginine-NO-cGMP signalling pathway in pancreatitis

45. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at theABCG5/8lithogenic locus

46. Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC).

47. Tu1041 “Healthy Liver” in Morbidly Obese: Transition to NASH in the Context of Insulin Resistance as Prerequisite for Hepatic Steatosis Requires Additional Triggers

48. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Catalog

Books, media, physical & digital resources